About this trial
Down syndrome (DS) is associated with cognitive deficits, caused by alterations in neuroplasticity and synaptic transmission. Non-invasive brain stimulation techniques, such as transcranial direct current stimulation (tDCS), can modulate the brain's plasticity mechanisms and neurotransmitter balance.
Anodal tDCS increases cortical excitability by depolarizing neurons, while cathodal tDCS decreases it through hyperpolarization. When combined with cognitive training, tDCS may produce faster and longer-lasting therapeutic effects. Although most of the neurorehabilitation studies have applied anodal excitatory stimulation, recent evidence suggests the potential cathodal inhibitory stimulation in neurodevelopmental disorders with alteration of synaptic transmission, as people with DS. Potentially both anodal and cathodal stimulation protocols could lead to positive clinical effects in DS.
This proof-of-concept study is a double-blind, placebo-controlled, clinical trial aiming to evaluate the efficacy of two active tDCS protocols (anodal and cathodal) targeting the left inferior frontal gyrus (IFG) versus sham stimulation tDCS, combined with speech and language training, to improve language skills in adolescents and young adults with DS. The study also aims to identify the most effective parameters of tDCS treatment, for customization in adolescents and young adults with DS. Thirty-six participants, aged 12 to 21 years, will be randomly assigned to three groups receiving anodal, cathodal, or sham tDCS. Each participant will undergo 10 sessions of tDCS at 1 mA for 20 minutes, alongside speech and language training five times for two weeks.
Neuropsychological, behavioral, biomarker (including brain-derived neurotrophic factor and neurofilament light chain), and electroencephalogram assessments will be performed at baseline, post-treatment, and three months after treatment completion. The study hypothesizes that tDCS will enhance language abilities, particularly expressive vocabulary, and modulate biomarkers of brain plasticity in DS participants. The study also hypothesizes that tDCS will enhance other cognitive and behavioral functions. Since tDCS effects may last, the study will check for improvements at the three-month. If effective, this combined approach of tDCS and language training could pave the way for new rehabilitation strategies for DS.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Italian speakers participants of both genders with the presence of a free trisomy 21 documented by karyotyping
Adolescents and young adults from 12 to 21 years old
Mental age ≥ 4 years (as assessed by Leiter-3 at baseline)
Scores < 2 SD at the denomination subtest of BVL_4-12
Disqualifiers
The presence of any neurosensory deficits, such as hypoacusis or serious visual impairments
The presence of epilepsy, familiarity with epilepsy and major psychopathological disorders
Scores < 10 points at the denomination subtest of BVL_4-12
Ability to verbally imitate less that 7 of 10 words during an imitation screening task
Trial design
Parallel
Treatments tested in this trial
Active Group (Active Anodal tDCS to the left IFG or Cathodal tDCS to the left IFG)
DeviceParticipants in the active tDCS group (Anodal tDCS or Cathodal tDCS) will receive stimulation set at 1 mA (milliampere), with a duration of 20 minutes per session. The stimulation will be administered in five consecutive sessions per day, five days a week, for two weeks, totaling 10 sessions, while participants will also undergo logopedic treatment for 20 minutes. The training protocol will consist of 10 minutes of training in motor planning and programming abilities and 10 minutes of training on the lexical, morphosyntactic, and functional aspects of language and communication.
Sham Group
DeviceFor the sham condition, the same electrode placement will be used as in the anodal tDCS condition, but the current will be applied for 30 s and will be ramped down without the participant's awareness. Stimulation intensity will be set at 1 mA; the duration of stimulation will be 20 min and will be held five consecutive daily session per week for two weeks, for a total of 10 sessions. During the tDCS sessions participant will sit in a comfortable chair and a language training will be administered
Treatment groups
Trial outcomes
Primary outcomes
Expressive Vocabulary
The primary outcome measure will be expressive vocabulary assessed by the Naming subtests of the Battery for the Assessment of Language in Children aged 4 to 12 years (BVL\_4-12).
Secondary outcomes
Articulation, Semantic Fluency and Phonological Fluency
These subtests from the Battery for the Assessment of Language in Children aged 4 to 12 years (BVL\_4-12) assess various language abilities: articulation evaluates the clarity of speech sounds; naming measures the ability to retrieve and produce the correct names of pictured objects; semantic fluency tests the capacity to generate words within a given category; and phonological fluency assesses the ability to produce words beginning with specific letters. Together, these measures provide a comprehensive evaluation of expressive language skills in participants.
Adaptive level
Adaptive Behavior Assessment System - Second Edition (ABAS-II) Scale to obtain the parent's observations about the youth's behaviour and gives a complete overview of child and adolescent adaptive behaviours.
Psychopathological measure - behavioral and psychopathological aspects
Conners' Parent Rating Scale - Revised, Long Form (CPRS-R:L). Questionnaire used parent's observations about the youth's behaviour and gives a complete overview of child and adolescent psychopathological disorders.The T scores of each scale of the questionnaire will also be evaluated.
Psychopathological measure - behavioural and emotional problems
Child Behavior Checklist for Ages 6-18 (CBCL/6-18) Questionnaire assesses behavioural and emotional problems in children and young people aged 6-18 years.The T scores of each scale of the questionnaire will also be evaluated.
Other outcomes
Biological measures
The evaluation of Brain-Derived Neurotrophic Factor (BDNF) and Neurofilament Light Chain (NfL) levels is performed through the collection of blood samples. Blood samples will be collected by venipuncture between 8 and 10 pm at baseline (T0), at the end of treatment (T1) and after three months (T2). Plasma levels of BDNF and NfL will be measured by enzyme-linked immunosorbent assay (ELISA) according to the procedures supplied by the manufacturer (DuoSet, R\&D Systems, Minneapolis, MN, USA). Analyses of blood samples were also performed blind to group assignment and outcome. The BDNF content and the NfL will be measured on plasma samples obtained from 7 cc blood collected in EDTA tubes, centrifuged at 1000 x g for 15 min, and immediately stored at -20°C avoiding repeated freeze-thaw cycles.
Neurophysiological measures
Electroencephalogram (EEG) is a method to record an electrogram of the electrical activity on the scalp that has been shown to represent the macroscopic activity of the surface layer of the brain underneath. Resting-state EEG will be recorded in a sound-attenuated, electrically shielded room through a 8-channels positioned close to the region of interest (IFG), reusable pre-wired headcap system to minimize preparation time. Participants will be instructed to sit comfortably and relax. A minimum time of 5-minutes EEG activity with eyes closed will be recorded. EEG signals will be amplified at a sampling rate of 1000 Hz using a 0.1-100 Hz online bandpass filter. For each channel, a 0.5-45 Hz offline, digital bandpass filter will be applied, and electrode impedance will be kept below 50 k omega. To reduce artifacts, Curry 7 will be used for EEG data pre-processing.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Floriana Costanzo
Lead sponsor
Bambino Gesù Hospital and Research Institute
Sponsor institution
Bambino Gesù Children's Hospital IRCCS
Collaborator